Physiogenex will be presenting a study dealing with the effects of obeticholic acid and elafibranor in various animal models of NASH/hepatic fibrosis.
The study will be presented by Dr. François Briand, Director of Research and Business Development, during the poster session on Friday, September the 14th, from 11:45am to 1:15pm, poster #10.

If you wish to make an appointment during the meeting with Dr. François Briand to discuss about your drug development project, please contact us.